Cuorips

Cuorips Inc. is a Japanese regenerative-medicine company based in Tokyo that is working to bring human (allogeneic) iPS cell-derived cardiomyocyte sheets into clinical and commercial use. Its name combines "Cuore," the Italian word for heart, with "iPS," reflecting its founding focus on the heart. The company describes itself as a professional group that unites world-leading iPS cell technology with cutting-edge science to tackle diseases that were previously untreatable. Cuorips' first major challenge is the commercialization of its cardiomyocyte sheet product, ReHeart®. The company positions this as only the first step toward next-generation medicine. It is also pursuing catheter-based treatments designed to minimize physical burden on patients, and innovative compounds known as the YS series that aim to regenerate tissues throughout the body through oral medicines or injections. A central element of Cuorips' strategy is VMaCS, a consortium formed with support from Japan's Ministry of Economy, Trade and Industry (METI). The consortium aims to implement a cell mass-manufacturing system in Japan to promote the development of next-generation cell-based modalities. Cuorips contributes manufacturing technology and know-how cultivated through its iPS cell-derived cardiomyocyte sheets, and the consortium brings together private companies with expertise in cell mass-culture systems to support the global expansion of drug-discovery ventures and access to overseas markets. The company operates CLiC-1 (Cuorips Labo-integrated Cell Processing Facility for Advanced Therapy-1st), a lab-integrated manufacturing facility based on a unique design concept. CLiC-1 provides one-stop services covering production process development through manufacturing and quality control of regenerative-medicine products and specified cell-processed products, and it also supports contract development and manufacturing (CDMO) for cell culture processing. The facility holds specified cell-processed product facility registration number FC5260014 and regenerative-medicine product manufacturing license number 27F1X10005. Cuorips has also presented its iPS cardiomyocyte sheet at Expo 2025-related legacy events in Osaka, and its leadership has been featured in Japanese media interviews about the 20-year history of iPS cells. The company's stated mission is to create new medicine and contribute to the health and lives of people around the world, with the slogan "Move hearts, connect lives."

Cuorips Inc. is a Japanese regenerative-medicine company headquartered in Tokyo. Its name derives from "Cuore," the Italian word for heart, and "iPS," the abbreviation for induced pluripotent stem cells, reflecting the company's founding focus on cardiac regeneration using iPS cell technology. The company's first major undertaking has been the development and commercialization of a human (allogeneic) iPS cell-derived cardiomyocyte sheet, which it describes as the world's first such sheet. This product is marketed under the name ReHeart®. Cuorips positions the social implementation (commercialization) of ReHeart® as only the first step toward next-generation medicine, and it is also pursuing catheter-based treatments designed to reduce patient burden and innovative compounds (the YS series) intended to regenerate tissues throughout the body via oral medicines or injections. A significant strategic development has been the formation of the VMaCS consortium, established with support from Japan's Ministry of Economy, Trade and Industry (METI). The consortium aims to implement a cell mass-manufacturing system in Japan to promote the development of next-generation cell-based modalities. Cuorips contributes manufacturing technology and know-how cultivated through its iPS cell-derived cardiomyocyte sheets, and the consortium brings together private companies with expertise in cell mass-culture systems to support the global expansion of drug-discovery ventures and access to overseas markets. The company operates CLiC-1 (Cuorips Labo-integrated Cell Processing Facility for Advanced Therapy-1st), a lab-integrated manufacturing facility based on a unique design concept. CLiC-1 provides one-stop services covering production process development through manufacturing and quality control of regenerative-medicine products and specified cell-processed products, and it also supports contract development and manufacturing (CDMO) for cell culture processing. The facility holds specified cell-processed product facility registration number FC5260014 and regenerative-medicine product manufacturing license number 27F1X10005. Its design uses semi-open airflow-controlled booths, including an air barrier booth from Daidan, to achieve efficient manufacturing with high local cleanliness control and reduced microbial contamination risk. Cuorips has also engaged in public outreach, exhibiting its iPS cardiomyocyte sheet at Expo 2025-related legacy events in Osaka and participating in media interviews about the 20-year history of iPS cells. The company's stated mission is to create new medicine and contribute to the health and lives of people around the world, with the slogan "Move hearts, connect lives."

• Takayuki Kusanagi appointed as Director of the company

• Takayuki Kusanagi appointed as Representative Director, President and CEO

• Tadayuki Tanimura appointed as Executive Officer (responsible for regulatory affairs)

• Tadayuki Tanimura appointed as Director, Vice President and General Manager of Administration

• Kazuyoshi Hirao appointed as Director and Chief Business Officer

• Kazuyoshi Hirao appointed as Director, Vice President and Chief Business Officer

Regenerative medicine company commercializing iPS cell-derived cardiomyocyte sheets and building cell manufacturing infrastructure.

• ReHeart®

  Human (allogeneic) iPS cell-derived cardiomyocyte sheet, described as the world's first such sheet.

• YS series

  Innovative compounds intended to regenerate tissues throughout the body via oral medicines or injections.

• CLiC-1

  Lab-integrated cell processing facility providing one-stop development, manufacturing and quality control services, including CDMO services.

1. 1クオリプス株式会社｜ヒト(同種) iPS 細胞由来心筋細胞シートで再生医療を社会実装cuorips.co.jp
2. 2ABOUTUS｜クオリプス株式会社cuorips.co.jp
3. 3事業所紹介｜クオリプス株式会社cuorips.co.jp
4. 4Cuorips Inc. (Japan) - Wikidatawikidata.org